Pharma and Biopharma Outsourcing Association

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

The commitment will include new, state-of-the-art R&D facilities as well as new or expanded manufacturing sites in multiple states.

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Calculating the amount of drug needed for compounding requires different considerations for respective drug types and forms.

The new United Kingdom-based firm has sites located in France, Spain, and Sweden, thanks to an acquisition of Synerlab Group and several Recipharm facilities in 2024.